Panna Sharma

Lantern Pharma Subsidiary Starlight Therapeutics Names New Chief Medical Officer to Oversee Clinical Trials

by | Jan 19, 2024

Marc Chamberlain, M.D., has been appointed as the Chief Medical Officer at Starlight Therapeutics.

Starlight Therapeutics is a Dallas-based Lantern Pharma subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective therapeutic options.

In his role as CMO, Chamberlain will oversee the company’s upcoming clinical trials focused on several serious and complex brain-related conditions: glioblastoma and other high-grade gliomas (aggressive types of brain tumor), brain metastases in adults (secondary brain tumors originating from cancer elsewhere in the body), and two types of pediatric brain tumors — atypical teratoid rhabdoid tumors (ATRT) and diffuse intrinsic pontine glioma (DIPG)....

MORE
Busting the Brain’s Firewall: How Lantern Pharma’s Algorithms Can Predict a Drug’s Ability to Reach the Brain
by | May 2, 2023
The "blood-brain barrier" acts like a highly selective firewall, preventing an estimated 98% of drugs from entering the brain—making it a major hurdle in the development of brain and central nervous system drugs. Lantern Pharma has recently developed what it calls "highly accurate AI algorithms" to predict the ability of a drug or compound to pass through the barrier.
MORE
Lantern Pharma Adds VP of Clinical Development, Additional Team Members
by | Mar 2, 2023

Dallas-based Lantern Pharma Inc. has expanded its clinical development team with the addition of Dr. Reggie Ewesuedo as vice president of clinical development, and several additional team members....

MORE
Lantern Pharma’s New Drug Candidate for Mantle Cell Lymphoma Shows Promise
by | Dec 22, 2022
The Dallas-based biopharmaceutical company expects to begin testing the drug candidate in a “first in human” trial in mid-2023. The drug was developed using the publicly traded company’s AI/ML drug development platform.

Lantern, in collaboration with the National Cancer Institute, recently published insights on how AI can be used to find new indications for cancer drugs in record times with significant reductions in costs.
MORE
Lantern Pharma cancer

Lantern Pharma Teams Up with National Cancer Institute to Predict Drug Effectiveness on Tumors

by | Oct 7, 2019
This alum of Dallas startup accelerator Health Wildcatters is working with the National Cancer Institute's Developmental Therapeutics Branch on precision research and treatments.
MORE